Thanks again doubleJ23. I agree that they are concerned about NOT repeating the PolyMedix mistakes that PYMX did with their other drug candidate, having side effects that prevented approval. I think that it's wise to start with the smallest effective dose to get approval, even if it means that it may be effective for a smaller percentage of patients. Doctors can always give a larger dose to a very heavy patient (assuming it's dependent on body weight), or a second dose, if necessary.

We speculated at the beginning of the Kevetrin trial that they were starting with such small doses for the same reason -- completely new type of drug, wanting to be sure they didn't harm patients with an untested drug. Safety seems paramount to CTIX.

I certainly appreciate your very specific summary of your impressions of the meeting.